Mclena-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease; Trial Design and Rationale

Authors

Boris DecourtFollow

Disciplines

Clinical Trials | Medical Immunology | Medical Neurobiology | Medical Pharmacology | Medical Sciences | Medicine and Health Sciences | Nervous System Diseases | Neurosciences

Document Type

Event

Recommended Citation

Decourt, Boris, "Mclena-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease; Trial Design and Rationale" (2023). Annual Research Symposium. 27.
https://ecommons.roseman.edu/researchsymposium/2023/postergroup5/27